Aβ42 and Aβ40: similarities and differences

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Alzheimer's disease (AD) is characterized by the abnormal accumulation of amyloid-beta (Aβ) peptides in the brain.
• Aβ peptides are derived from the amyloid precursor protein (APP) through proteolytic cleavage.
• The amyloid hypothesis posits that Aβ accumulation drives AD pathogenesis.

Purpose of the Study:

• To review and compare the similarities and differences between Aβ40 and Aβ42 isoforms.
• To discuss the distinct metabolism, physiological functions, toxicities, and aggregation mechanisms of Aβ40 and Aβ42.
• To highlight recent advancements in selective inhibitors and probes targeting these Aβ isoforms.

Main Methods:

• Literature review and synthesis of existing research on Aβ peptides.
• Comparative analysis of biochemical and functional properties of Aβ40 and Aβ42.
• Summary of studies on therapeutic strategies and diagnostic tools.

Main Results:

• Aβ40 and Aβ42, despite differing by only two amino acids, exhibit significant variations.
• These variations impact their aggregation propensity, toxicity, and roles in AD.
• Selective inhibitors and probes are being developed to target specific Aβ isoforms.

Conclusions:

• Understanding the differential characteristics of Aβ40 and Aβ42 is critical for AD research.
• Targeting specific Aβ isoforms offers a promising therapeutic avenue.
• Further research into selective inhibitors and probes is essential for developing effective AD treatments.